Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Fennec Pharmaceuticals Inc shares valued at $170,048 were sold by Southpoint Capital Advisors LP on Nov 18 ’25. At $8.79 per share, Southpoint Capital Advisors LP sold 19,341 shares. The insider’s holdings dropped to 3,744,741 shares worth approximately $29.55 million following the completion of this transaction.
Also, Southpoint Capital Advisors LP sold 160,100 shares, netting a total of over 1,280,432 in proceeds. Following the sale of shares at $8.00 each, the insider now holds 3,850,000 shares.
Before that, Southpoint Capital Advisors LP had sold 85,918 shares from its account. In a trade valued at $755,193, the 10% Owner traded Fennec Pharmaceuticals Inc shares for $8.79 each. Upon closing the transaction, the insider’s holdings decreased to 85,918 shares, worth approximately $29.7 million.
As published in a research note from Cantor Fitzgerald on November 22, 2022, Fennec Pharmaceuticals Inc [FENC] has been rated up from a Neutral to an Overweight and the price target has been revised to $12 from $9. Analysts at CapitalOne started covering the stock with ‘”an Overweight”‘ outlook in a report released in early September. Earlier on June 05, 2020, Cantor Fitzgerald initiated its rating. Their recommendation was “an Overweight” for FENC stock.
Analyzing FENC Stock Performance
On last trading session, Fennec Pharmaceuticals Inc [NASDAQ: FENC] plunged -0.75% to $7.89. The stock’s lowest price that day was $7.72, but it reached a high of $8.0 in the same session. During the last five days, there has been a drop of approximately -3.55%. Over the course of the year, Fennec Pharmaceuticals Inc shares have jumped approximately 48.31%. Shares of the company reached a 52-week high of $9.92 on 10/06/25 and a 52-week low of $4.68 on 04/09/25.
Support And Resistance Levels for Fennec Pharmaceuticals Inc (FENC)
According to the 24-hour chart, there is a support level at 7.74, which, if violated, would cause prices to drop to 7.59. In the upper region, resistance lies at 8.02. The next price resistance is at 8.15. RSI (Relative Strength Index) is 44.45 on the 14-day chart, showing neutral technical sentiment.
Is Fennec Pharmaceuticals Inc subject to short interest?
Stocks of Fennec Pharmaceuticals Inc saw a sharp steep in short interest on 2025-11-14 dropping by -0.23 million shares to 1.07 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 1.31 million shares. A decline of -21.86% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 10.53 of the overall float, the days-to-cover ratio (short ratio) decline to 10.53.
Which companies own the most shares of Fennec Pharmaceuticals Inc (FENC)?
In terms of Fennec Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 14 in the next 12 months, up nearly 76.1% from the previous closing price of $7.95. Analysts anticipate Fennec Pharmaceuticals Inc stock to reach 14 by 2025, with the lowest price target being 14. In spite of this, 12 analysts ranked Fennec Pharmaceuticals Inc stock as Buy at the end of 2025.
